Literature DB >> 16799896

Long-term effect of bezafibrate on parameters of hepatic fibrosis in primary biliary cirrhosis.

Kenji Ohmoto, Naoko Yoshioka, Shinichiro Yamamoto.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799896     DOI: 10.1007/s00535-006-1778-1

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  5 in total

1.  Effect of bezafibrate in primary biliary cirrhosis: a pilot study.

Authors:  K Ohmoto; Y Mitsui; S Yamamoto
Journal:  Liver       Date:  2001-06

2.  Long-term fibrate treatment for PBC.

Authors:  Makoto Nakamuta; Munechika Enjoji; Kazuhiro Kotoh; Naoya Shimohashi; Yuichi Tanabe
Journal:  J Gastroenterol       Date:  2005-05       Impact factor: 7.527

Review 3.  Detection of hepatic fibrogenesis: a review of available techniques.

Authors:  J Wu; A Danielsson
Journal:  Scand J Gastroenterol       Date:  1995-09       Impact factor: 2.423

4.  Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.

Authors:  Xavier Forns; Sergi Ampurdanès; Josep M Llovet; John Aponte; Llorenç Quintó; Eva Martínez-Bauer; Miquel Bruguera; Jose Maria Sánchez-Tapias; Juan Rodés
Journal:  Hepatology       Date:  2002-10       Impact factor: 17.425

5.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

  5 in total
  11 in total

1.  Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Authors:  Runalia Bahar; Kimberly A Wong; Chung H Liu; Christopher L Bowlus
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-03

2.  Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.

Authors:  Atsushi Tanaka; Junko Hirohara; Yasuni Nakanuma; Hirohito Tsubouchi; Hajime Takikawa
Journal:  J Gastroenterol       Date:  2014-09-20       Impact factor: 7.527

Review 3.  New therapies for primary biliary cirrhosis.

Authors:  Annarosa Floreani; Irene Franceschet; Lisa Perini; Nora Cazzagon; M Eric Gershwin; Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 4.  Fibrates and cholestasis.

Authors:  Nisanne S Ghonem; David N Assis; James L Boyer
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

5.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

Review 6.  Proposed therapies in primary biliary cholangitis.

Authors:  Annarosa Floreani; Ying Sun; Zheng Sheng Zou; Baosen Li; Nora Cazzagon; Christopher L Bowlus; M Eric Gershwin
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2016-01-06       Impact factor: 3.869

7.  Fenofibrate in primary biliary cirrhosis: a pilot study.

Authors:  E N Liberopoulos; M Florentin; M S Elisaf; D P Mikhailidis; E Tsianos
Journal:  Open Cardiovasc Med J       Date:  2010-04-28

8.  Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.

Authors:  Nisanne S Ghonem; James L Boyer
Journal:  Hepatology       Date:  2013-04-05       Impact factor: 17.425

Review 9.  Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.

Authors:  Francesca Saffioti; Kurinchi Selvan Gurusamy; Leonardo Henry Eusebi; Emmanuel Tsochatzis; Brian R Davidson; Douglas Thorburn
Journal:  Cochrane Database Syst Rev       Date:  2017-03-28

Review 10.  A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis.

Authors:  Vinod S Hegade; Ruth Bolier; Ronald Pj Oude Elferink; Ulrich Beuers; Stuart Kendrick; David Ej Jones
Journal:  Frontline Gastroenterol       Date:  2015-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.